As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...
The FDA has granted traditional approval to brexucabtagene autoleucel (Tecartus; brexu-cel) for treatment of adult patients ...
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in ...
March 8, 2011 (Boston, Massachusetts) — Raltegravir (Isentress, Merck) is the antiretroviral drug of choice for treatment-naïve HIV-infected patients. Results from the QDMRK trial indicate that ...
Myelofibrosis morbidity is driven by splenomegaly, systemic symptoms, and anemia; discontinuation of JAK inhibitors exceeds ...
The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Investigators sought to examine the real-world risk of developing keratinocyte carcinoma among patients with atopic dermatitis using ruxolitinib cream 1.5%.
Opioids are the mainstay of cancer pain treatment, and many of the guideline changes deal with how these agents should be selected and used in cancer patients. New to the adult cancer pain guidelines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results